KPTI Stock Overview
A commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Karyopharm Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.72 |
| 52 Week High | US$1.95 |
| 52 Week Low | US$0.58 |
| Beta | 0.072 |
| 1 Month Change | -1.78% |
| 3 Month Change | -16.86% |
| 1 Year Change | -3.78% |
| 3 Year Change | -91.09% |
| 5 Year Change | -95.80% |
| Change since IPO | -95.54% |
Recent News & Updates
Recent updates
Lacklustre Performance Is Driving Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) 27% Price Drop
Dec 24
Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S
Oct 01Karyopharm Therapeutics Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 09Benign Growth For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Underpins Stock's 28% Plummet
Apr 27Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%
Feb 23Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)
Feb 05Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified
Apr 17Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Apr 17Karyopharm: Market Is Overlooking Growth
Oct 07Karyopharm Therapeutics Q2 2022 Earnings Preview
Aug 03Karyopharm cancer therapy eltanexor gets FDA fast track status, orphan drug tag in EU
Jul 20Shareholder Returns
| KPTI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.2% | 1.2% | 0.7% |
| 1Y | -3.8% | -7.0% | 23.0% |
Return vs Industry: KPTI exceeded the US Biotechs industry which returned -7% over the past year.
Return vs Market: KPTI underperformed the US Market which returned 23% over the past year.
Price Volatility
| KPTI volatility | |
|---|---|
| KPTI Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KPTI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KPTI's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 325 | Richard Paulson | www.karyopharm.com |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Karyopharm Therapeutics Inc. Fundamentals Summary
| KPTI fundamental statistics | |
|---|---|
| Market cap | US$89.73m |
| Earnings (TTM) | -US$87.48m |
| Revenue (TTM) | US$148.44m |
0.6x
P/S Ratio-1.0x
P/E RatioIs KPTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KPTI income statement (TTM) | |
|---|---|
| Revenue | US$148.44m |
| Cost of Revenue | US$16.72m |
| Gross Profit | US$131.72m |
| Other Expenses | US$219.20m |
| Earnings | -US$87.48m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.70 |
| Gross Margin | 88.73% |
| Net Profit Margin | -58.93% |
| Debt/Equity Ratio | -165.4% |
How did KPTI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 02:44 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Karyopharm Therapeutics Inc. is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Peter Lawson | Barclays |
| Ying Huang | BofA Global Research |